Patterns of response and relapse in chemotherapy of extensive squamous carcinoma of the lung

Related Experiment Videos

R B Livingston, L H Heilbrun

Cancer Chemotherapy and Pharmacology

|January 1, 1978

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.

Breast cancer research and treatment·2016

Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer.

The pharmacogenomics journal·2013

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.

Annals of oncology : official journal of the European Society for Medical Oncology·2012

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.

Annals of oncology : official journal of the European Society for Medical Oncology·2008

Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study.

Annals of oncology : official journal of the European Society for Medical Oncology·2005

The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2002

See all related articles